Cerevance
Boston
About Cerevance
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, the company generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $189.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2024)
- Website: cerevance.com
Industries & Categories
Biotechnology, Life Science, Medical, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cerevance-60868 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.